Afami-cel (afamitresgene autoleucel; formerly ADP-A2M4), an adoptive T-cell receptor therapy targeting the MAGE-A4 cancer antigen, achieved clinically significant results for patients with multiple solid tumor types in a phase I clinical trial led by researchers at MD Anderson Cancer Center.
Jeffrey E. Lee was appointed chief medical executive at The University of Texas MD Anderson Cancer Center, effective April 1.
